How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Want to cut your energy bills? Here’s how five experts are doing it 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
NEW YORK, May 26, 2017 -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Intra-Cellular Therapies, Inc. securities (NASDAQ:ITCI) from August 12, 2014 through April 28, 2017, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Intra-Cellular Therapies investors under the federal securities laws.
To join the Intra-Cellular Therapies class action, go to http://www.rosenlegal.com/cases-1111.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) findings related to toxicity in animals treated with lumateperone (ITI-007) were observed; (2) these findings posed an additional safety concern regarding lumateperone; and (3) as a result, Intra-Cellular Therapies’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 11, 2017. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-1111.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com
